Oncology & Cancer

Oncology clinical trials decline during pandemic

The COVID-19 pandemic was associated with a 60 percent decrease in the number of launches of oncology clinical trials of drugs and biologic therapies, according to a research letter published online Jan. 27 in JAMA Network ...

Medications

Recommendations provided for treatment of ulcerative colitis

(HealthDay)—In a new clinical guideline from the American Gastroenterological Association, recently published in Gastroenterology, treatment recommendations are presented for patients with moderate-to-severe ulcerative ...

Medical research

Safer viruses for vaccine research and diagnosis

A new technology to produce safer 'hybrid' viruses at high volumes for use in vaccines and diagnostics for mosquito-borne diseases has been developed at The University of Queensland.

Inflammatory disorders

Two new studies evaluate agents for treating ulcerative colitis

In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. ...

Diseases, Conditions, Syndromes

Side effects of biologics for rheumatic Dz may up anxiety

(HealthDay)—Potential side effects of biological agents may increase anxiety in patients with rheumatic disease, according to research published in the June issue of the International Journal of Rheumatic Diseases.

Parkinson's & Movement disorders

Toward a better understanding of Parkinson's disease

A new study, published today in Nature Structural and Molecular Biology, moves researchers closer to understanding one of the crucial proteins involved in Parkinson's disease.

page 2 from 8